Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 36.18B P/E - EPS this Y -27.60% Ern Qtrly Grth -
Income -750.23M Forward P/E -158.18 EPS next Y 65.30% 50D Avg Chg -1.00%
Sales 2.3B PEG 0.55 EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 13.83 EPS next 5Y -98.70% 52W High Chg -7.00%
Recommedations 2.50 Quick Ratio 1.96 Shares Outstanding 188.66M 52W Low Chg 66.00%
Insider Own 0.81% ROA -12.94% Shares Float 129.83M Beta 0.32
Inst Own 88.83% ROE -27.93% Shares Shorted/Prior 9.58M/10.42M Price 192.98
Gross Margin 7.46% Profit Margin -32.61% Avg. Volume 1,305,783 Target Price 229.00
Oper. Margin -35.20% Earnings Date Feb 13 Volume 672,976 Change 0.28%
About Seagen Inc.

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

SGEN Chatroom

User Image Power2k Posted - 1 week ago

$VKTX $PFE "Pfizer reiterated its expectation that the Seagen acquisition will bring in $10 billion in sales by 2030. " "Analysts at William Blair responded to the news by raising their peak sales estimate for Viking to $14.4 billion in the US and $7.2 billion in Europe from previous valuations of $10.1 billion and $3.6 billion, respectively." That gives the combined sales of $21.2 billion (from VK2735) which does not even include potential sales from VK2809 IMO. Pfizer's $43 billion Seagen $SGEN acquisition doubled its oncology drug pipeline to 60 different experimental programs - however could generate only $10 billion peak sale - less than half of what Viking's assets can bring in. If Bourla does eventually let this Viking Weight Loss/NASH opportunity slid away, his tenue at Pfizer as the CEO shall come to an end pretty soon.

User Image ians Posted - 1 week ago

@oex2500 Good to know they still have cash left over after the $SGEN deal. Oncology + Cardio-metabolic portfolio could allow them to be re-rated. That is IF they win the bidding war 😉 ☘️💎

User Image SM07 Posted - 2 weeks ago

@biochirp That happened to $SGEN too, incidentally…

User Image SM07 Posted - 2 weeks ago

$CYTK will end up like $SGEN with an even higher bid few months later.

User Image Recard159 Posted - 3 weeks ago

$SGEN just laid off the entire team from their "launchpad" site in Everett. I'm surprised not to see this news in the chat.

User Image HunterT Posted - 3 weeks ago

$SGEN In case you want to follow the money…

User Image HunterT Posted - 3 weeks ago

$SGEN FYI Clays new company is $IMNM thank me later…. Seagen 2.0💪🏻

User Image ReactionAction Posted - 4 weeks ago

$TLIS Baker Bros average? $120/share with private financing prior to IPO Greenlight Capital average? $75/share bought in early 2022 TD Cowen advising independent board for strategic alternatives. Covid failure for Baker bros. Now they need to recover $300 million. Not a pocket change. Remember Baker has cash that need to put into work after $SGEN acquisition. PIPE financing probable with reverse merger

User Image GreenTsunami Posted - 1 month ago

$VINC $PYXS I am waiting patiently for the next wave. Trust Tsunami once clinical data is released this is easily going to be a big one to to ride! ADC breakthroughs have gone from being a novelty money maker to over a 9 billion dollar industry in the last 5 years and it's setting up now to be backbone of new money revenue for big pharma. Just look at $SGEN $43 billion buyout. Both these companies will get bought out within a year if clinical data proves the science 🧪 Tomorrow we leap towards March results.

User Image ern1in Posted - 1 month ago

$SGEN & $TGTX ...... Investment ideas💡

User Image ohyesarooni Posted - 1 month ago

$ILMN $IMMU $REGN $SGEN $ICU only thing better than a POST is a rePOST

User Image ohyesarooni Posted - 1 month ago

$ILMN $IMMU $REGN $SGEN $ICU Somebody gets it POST

User Image mojorising44 Posted - 1 month ago

$ICU ZOOM OUT: The scope of SCD applications is truly massive BUT consider only the indications for which FDA has already granted Breakthrough Device Designation (AKI, Cardiorenal Syndrome & Hepato-Renal Syndrome). That’s over 1.3 million US patients yearly. With a single treatment course per year at a wholesale acquisition cost of $10-20K, that’s an annual revenue of $13-26 Billion (only US market). Using lowest cost ($10K) and only 20% adoption rate (even though SCD is poised to become the new standard of care) and it’s still $5.2B rev, not including international markets where they have patents. Even a 3% adoption rate makes this a billion dollar company, however the stellar advisory board profile ensures much higher market penetration. Patents in place, clinically proven efficacy, extremely safe, no competition,1/10th the cost of current practice with no additional equipment to purchase. Hold for 120X like $IMMU, $ILMN, $REGN, $SGEN

User Image jonnj Posted - 1 month ago

@TheGunnerAB It'll be $40 billion like $SGEN .

User Image swingingtech Posted - 1 month ago

$PFE $SGEN $MRNA $MRK https://wallstreetwaves.com/pfizer-surprises-with-profit-but-revolutionizing-cancer-treatment-is-its-best-chance-of-g

User Image STOCKPICKERTRADER Posted - 2 months ago

$PFE share price back at 2014 levels when company now has at least 30-45% more revenues and a very strong +6.15% dividend with low fundamentals. Seems to have been kicked to the curb like several others in sector and unable to gain traction. Company cost cutting and digestion of $SGEN will likely have some impact this quarter, but otherwise there should be improvements in revenues and operating costs. Expecting positive improvements over any further negative pressures at these share price levels - imho Very hated stock in need of some AI makeover and hype to join the elite club of overextended valuations ;-)

User Image ViractaTrader77 Posted - 2 months ago

$VINC Former $SGEN ceo rolling up ADC assets at $IMNM maybe they will takeout Vincerx…

User Image Harrysamuel92 Posted - 2 months ago

@Ernst_Grafenberg @shortvolume it did happened. $SGEN

User Image FE123 Posted - 2 months ago

$ALT Definitely think $MRK Will Buy $ALT over $PFE , PFE Outbid MRK for $SGEN and $MRK will not allow that with buyout of $ALT!! Come on $MRK Give us that Buyout News for $ALT!!!

User Image STOCKPICKERTRADER Posted - 2 months ago

$PFE just ignore the extreme noise and non-stop bashing and do your due diligence. Strong fundamentals, growing pipeline, $SGEN acquisition completed to add new product revenues and pipeline, super dividend play near 6% with low P/E. Company had 11% of ALL FDA approvals last year and will continue with this stronger than normal volume of submissions going forward. Small and large acquisitions over past couple years added to product/revenue breadth nearly double what it was at this share price back in 2016 area with 50% less dividend. Normalization of dividend back to the 4.5% area is a fairly conservative +20% share price increase (33-35 area). GO FISHING! Here to make money and not hate/love on a stock. GLTAL

User Image STOCKPICKERTRADER Posted - 2 months ago

@TwelveEggsInOneBasket that seems to be totally ignored by the markets. Even with stronger pipeline than ever before and solid fundamentals, this thing can't get moving again. However, I believe that in the coming weeks/months there will be flow of positive progress in product revenues and new FDA submissions/approvals to add to the story. $SGEN will kick in both some product revenue and pipeline value. Patiently collecting shares - $PFE

User Image STOCKPICKERTRADER Posted - 2 months ago

$PFE recent article about FDA approvals says it all - Pfizer had 11% of ALL FDA approvals last year and a strong pipeline going forward with $SGEN adding nicely!

User Image swingingtech Posted - 2 months ago

$PFE, $SGEN, $LLY, $MRK https://wallstreetwaves.com/pfizer-paying-too-much-to-boost-revenues/

User Image STCKPRO Posted - 2 months ago

$SGEN NEW ARTICLE : Pfizer: Paying Too Much To Boost Revenues https://www.stck.pro/news/SGEN/71822668/

User Image CryptoNewsAlerts Posted - 2 months ago

Pfizer (NYSE: PFE) Stock Drops Despite Positive Regulatory News on Hemophilia B Gene Therapy $PFE $SGEN https://abbonews.com/news/pfizer-nyse-pfe-stock-drops-despite-positive-regulatory-news-on-hemophilia-b-gene-therapy/

User Image StockInvest_us Posted - 2 months ago

Signal alert: $SGEN - GoldenStar https://stockinvest.us/l/bsSxhfsMMw

User Image StockInvest_us Posted - 2 months ago

Signal alert: $SGEN - GoldenStar https://stockinvest.us/l/0wI7kokAL2

User Image ViractaTrader77 Posted - 3 months ago

$IMNM should acquire $VINC for $100 million stock. Better pipe than Immunome has now in ADC's and SMDC's... $SGEN https://www.nature.com/articles/d43747-021-00011-3

User Image Aigner_Andreas Posted - 3 months ago

#DeathCross $SGEN at 124.00 R46 HiLo 24% T1Y 180 buy 2.1 PE 34.6 DIV N/A #Seagen Inc #stocks #trading #finance #market

User Image STCKPRO Posted - 3 months ago

$SGEN NEW ARTICLE : The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations https://www.stck.pro/news/SGEN/70936364/

Analyst Ratings
Truist Securities Hold Oct 18, 23
Truist Securities Hold Sep 25, 23
Morgan Stanley Equal-Weight Aug 3, 23
Berenberg Hold Mar 24, 23
TD Securities Market Perform Mar 21, 23
Truist Securities Hold Mar 20, 23
Morgan Stanley Equal-Weight Mar 15, 23
Oppenheimer Outperform Mar 14, 23
RBC Capital Outperform Mar 14, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Epstein David R CEO CEO Nov 10 Sell 213.01 10,620 2,262,166 136,598 11/13/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Nov 09 Sell 213.6 8,785 1,876,476 42,574 11/13/23
DANSEY ROGER D President, R&D & CMO President, R&D & CMO Mar 13 Sell 206.5 71 14,662 116,677 09/22/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Sep 21 Sell 206.5 80 16,520 51,359 09/22/23
LIU JEAN I Chief Legal Officer Chief Legal Officer Sep 21 Sell 206.5 64 13,216 84,398 09/22/23
ROMP CHARLES R EVP, Commercial U.S. EVP, Commercial U.S. Sep 21 Sell 206.5 45 9,292 69,111 09/22/23
SIMPSON TODD E Chief Financial Offi.. Chief Financial Officer Sep 21 Sell 206.5 80 16,520 128,723 09/22/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Sep 07 Sell 205.76 8,785 1,807,602 51,439 09/08/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Sep 07 Option 44.09 8,785 387,331 60,224 09/08/23
DANSEY ROGER D President, R&D & CMO President, R&D & CMO Aug 31 Sell 206.9659 4,029 833,866 111,768 09/01/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Aug 31 Sell 206.9659 1,795 371,504 51,439 09/01/23
LIU JEAN I Chief Legal Officer Chief Legal Officer Aug 31 Sell 206.9659 1,893 391,786 84,462 09/01/23
ROMP CHARLES R EVP, Commercial U.S. EVP, Commercial U.S. Aug 31 Sell 206.9659 555 114,866 69,156 09/01/23
SIMPSON TODD E Chief Financial Offi.. Chief Financial Officer Aug 31 Sell 206.9659 2,122 439,182 128,803 09/01/23
DANSEY ROGER D President, R&D & CMO President, R&D & CMO Aug 28 Sell 206 1,016 209,296 115,797 08/30/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Aug 28 Sell 206 371 76,426 53,234 08/30/23
ROMP CHARLES R EVP, Commercial U.S. EVP, Commercial U.S. Aug 28 Sell 206 438 90,228 69,711 08/30/23
SIMPSON TODD E Chief Financial Offi.. Chief Financial Officer Aug 28 Sell 206 485 99,910 130,925 08/30/23
LIU JEAN I Chief Legal Officer Chief Legal Officer Aug 28 Sell 206 405 83,430 86,355 08/30/23
WELCH DANIEL G Director Director Aug 28 Sell 209.08 4,925 1,029,719 10,725 08/29/23
WELCH DANIEL G Director Director Aug 28 Option 135.63 1,812 245,762 10,109 08/29/23
ROMP CHARLES R EVP, Commercial U.S. EVP, Commercial U.S. Jul 03 Sell 192.46 708 136,262 59,069 07/05/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Jun 07 Sell 195.29 16,215 3,166,627 43,837 06/09/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Jun 07 Option 41.04 16,215 665,464 60,052 06/09/23
ROMP CHARLES R EVP, Commercial U.S. EVP, Commercial U.S. May 16 Sell 189.8594 349 66,261 59,777 05/18/23
WELCH DANIEL G Director Director May 15 Sell 200.02 1,864 372,837 6,253 05/16/23
WELCH DANIEL G Director Director May 15 Option 135.63 1,864 252,814 8,117 05/16/23
WELCH DANIEL G Director Director May 01 Sell 200.07 27,032 5,408,292 12,335 05/03/23
WELCH DANIEL G Director Director May 01 Option 98.67 15,661 1,545,271 10,066 05/03/23
LIU JEAN I Chief Legal Officer Chief Legal Officer Apr 17 Sell 205.86 5,000 1,029,300 86,763 04/19/23
LIU JEAN I Chief Legal Officer Chief Legal Officer Apr 17 Option 39.15 5,000 195,750 91,763 04/19/23
DANSEY ROGER D President, R&D & CMO President, R&D & CMO Apr 17 Option 72.64 10,000 726,400 109,389 04/19/23
DANSEY ROGER D President, R&D & CMO President, R&D & CMO Apr 17 Sell 205.95 10,000 2,059,500 99,389 04/19/23
SIMPSON TODD E Chief Financial Offi.. Chief Financial Officer Apr 10 Sell 204.44 55,344 11,314,527 118,946 04/12/23
SIMPSON TODD E Chief Financial Offi.. Chief Financial Officer Apr 10 Option 46.37 55,344 2,566,301 159,310 04/12/23
SIMPSON TODD E Chief Financial Offi.. Chief Financial Officer Apr 05 Sell 205.86 243 50,024 118,946 04/07/23
ROMP CHARLES R EVP, Commercial U.S. EVP, Commercial U.S. Apr 05 Sell 205.86 133 27,379 60,126 04/07/23
LIU JEAN I Chief Legal Officer Chief Legal Officer Apr 05 Sell 205.86 174 35,820 86,763 04/07/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Apr 05 Sell 205.86 243 50,024 68,837 04/07/23
DANSEY ROGER D President, R&D & CMO President, R&D & CMO Apr 05 Sell 205.86 333 68,551 99,389 04/07/23
WELCH DANIEL G Director Director Apr 03 Sell 201.62 31,000 6,250,220 12,335 04/05/23
WELCH DANIEL G Director Director Apr 03 Option 58.69 17,525 1,028,542 7,011 04/05/23
WELCH DANIEL G Director Director Mar 13 Sell 200.96 27,397 5,505,701 24,306 03/16/23
WELCH DANIEL G Director Director Mar 13 Option 39.49 15,488 611,621 13,447 03/16/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Mar 02 Sell 177.5 16,215 2,878,162 67,257 03/03/23
HIMES VAUGHN B Chief Technical Offi.. Chief Technical Officer Mar 02 Option 41.04 16,215 665,464 69,948 03/03/23
SIMPSON TODD E Chief Financial Offi.. Chief Financial Officer Feb 16 Sell 160 39,946 6,391,360 137,185 02/21/23
SIMPSON TODD E Chief Financial Offi.. Chief Financial Officer Feb 16 Option 39.15 39,946 1,563,886 177,131 02/21/23
LIU JEAN I Chief Legal Officer Chief Legal Officer Feb 16 Sell 155 5,000 775,000 85,113 02/21/23
LIU JEAN I Chief Legal Officer Chief Legal Officer Feb 16 Option 39.15 5,000 195,750 90,113 02/21/23